Southoz, I haven't read past your post so I have another hour or...

Southoz,
I haven't read past your post so I have another hour or two ahead of me.
Your post is informative and well thought through.
Forgive me if others have posted similar ideas more recently.
I wonder if RAP m'ment should change their immediate approach.
Keep the aussie trials going in accordance with the statistical requirements of the FDA.
Direct immediate attention to getting device approval through aussie pathways and CE, and also what is required for asian pathway.
Keep and support DSF testing.
FDA approval could be working in the background, fixing up all the problems of the collection of data.
If the australian science / testing procedure was above reproach, it is difficult to see why todays announced results are so bad.
This is a test for management, today was a SP disaster.
I wish them well, but more importantly, we need progressive, confidant, strategic decision making.
Our management needs to be encouraged to get on the front foot.
I'm sure today's results were totally unexpected.
A key person to watch here, is Dr Porter's group. He knows if RAP works in a clinical setting.
RAP should think about trotting out some of their clinical admirals.
Bluey